. 2020 Aug 4;35(1):1581–1595. doi: 10.1080/14756366.2020.1801671

Table 2.

Results of the 5-dose in vitro human cancer cell growth inhibition^a for compounds 11a, 15a, and 15j and positive control Phenstatin.

Cell type	Compound	11a	11a	15a	15a	15j	15j	Phenstatin	Phenstatin
Cell type	Cell line	GI₅₀ (μM)	LC₅₀ (μM)	GI₅₀ (μM)	LC₅₀ (μM)	GI₅₀ (μM)	LC₅₀ (μM)	GI₅₀ (μM)	LC₅₀ (μM)
Leukaemia	K-562	0.036	>100	n.d.	n.d.	n.d.	n.d.	<0.010	>100
	HL-60(TB)	0.032	>100	2.58	>100	2.05	>100	0.011	>100
	SR	0.023	>100	2.90	>100	0.33	>100	<0.010	>100
	CCRF-CEM	0.055	>100	3.28	>100	1.75	>100	0.034	>100
	MOLT-4	0.077	>100	2.58	>100	2.04	>100	0.040	>100
	RPMI-8226	0.044	>100	n.d.	n.d.	n.d.	n.d.	0.037	>100
Non-small cell lung cancer	NCI-H460	0.042	>100	2.00	7.16	1.63	n.d.	0.033	>100
	NCI-H522	0.041	>100	2.13	>100	1.93	7.81	0.027	>100
	A549/ATCC	0.074	>100	3.29	>100	1.88	n.d.	0.057	>100
	HOP-62	0.051	>100	1.83	n.d.	1.78	n.d.	0.073	>100
Colon cancer	COLO205	0.035	>100	n.d.	n.d.	n.d.	n.d.	3.05	>100
	HCT-15	0.035	>100	2.62	>100	1.64	7.87	<0.010	>100
	HT29	0.037	>100	1.83	7.38	1.63	n.d.	2.95	>100
	SW-620	0.036	>100	1.76	6.83	1.38	7.70	<0.010	>100
	KM12	0.038	>100	1.81	6.46	1.93	n.d.	<0.010	>100
	HCT-116	0.053	>100	1.72	7.10	1.61	n.d.	0.038	>100
CNS cancer	SF-295	0.032	>100	1.86	n.d.	1.70	6.46	0.367	>100
	SF-539	0.053	>100	1.61	6.77	1.68	6.35	0.011	>100
	SNB-75	0.039	>100	1.46	7.77	1.47	6.50	<0.010	>100
	U251	0.053	>100	2.17	n.d.	1.70	7.39	0.043	>100
	SF268	0.088	>100	1.90	n.d.	1.86	n.d.	0.053	>100
	SNB-19	0.098	>100	2.12	n.d.	1.83	n.d.	0.031	>100
Melanoma	LOX IMVI	0.133	>100	1.87	n.d.	1.82	n.d.	0.013	>100
	M14	0.038	>100	1.91	n.d.	2.02	n.d.	<0.010	>100
	MDA-MB-435	<0.010	20.4	1.90	7.82	1.86	7.22	<0.010	>100
	UACC-62	0.031	>100	2.32	39.9	1.82	6.79	0.448	>100
	MALME-3M	0.089	>100	1.73	7.82	2.01	7.88	n.d.	>100
	SK-MEL-2	0.067	>100	2.60	>100	2.04	9.32	0.520	>100
	SK-MEL-5	0.041	>100	1.81	6.93	1.77	6.60	0.040	>100
Ovarian cancer	OVCAR-3	0.033	>100	1.83	7.11	1.88	7.08	0.021	>100
	NCI/ADR-RES	0.039	>100	>100	>100	3.16	>100	0.012	>100
	SK-OV-3	0.060	>100	19.6	>100	2.01	6.51	0.623	>100
Renal cancer	786-0	0.047	>100	1.75	6.58	1.80	n.d.	0.905	>100
	A498	0.027	>100	1.96	7.55	1.60	6.29	2.28	>100
	CAKI-1	0.066	>100	n.d.	n.d.	n.d.	n.d.	0.296	>100
	RXF 393	0.070	>100	1.66	7.27	1.40	6.57	0.016	>100
Breast cancer	MCF7	0.044	>100	1.79	n.d.	1.40	8.11	0.033	>100
	HS 578T	0.046	>100	1.74	25.0	1.81	>100	0.031	>100
	BT-549	0.060	>100	1.98	>100	1.87	n.d.	0.034	>100
	T-47D	0.051	>100	1.94	>100	1.83	n.d.	30.4	>100
	MDA-MB-468	0.094	>100	1.66	7.49	1.84	7.62	2.71	>100
Prostate cancer	PC-3	0.038	>100	2.61	>100	1.93	n.d.	0.045	>100
Prostate cancer	DU-145	0.090	>100	1.80	6.40	1.69	6.05	0.039	>100

GI₅₀: the molar concentration of tested compound causing 50% growth inhibition of tumour cells; LC₅₀: the molar concentration of tested compound causing 50% death of tumour cells; n.d.: not determined.

The most significant values are highlighted in bold.

^{^a}

Data obtained from NCI’s in vitro 60 cell 5-dose screening^35–37.